CA2403804A1 - Vegf-modulated genes and methods employing them - Google Patents

Vegf-modulated genes and methods employing them Download PDF

Info

Publication number
CA2403804A1
CA2403804A1 CA002403804A CA2403804A CA2403804A1 CA 2403804 A1 CA2403804 A1 CA 2403804A1 CA 002403804 A CA002403804 A CA 002403804A CA 2403804 A CA2403804 A CA 2403804A CA 2403804 A1 CA2403804 A1 CA 2403804A1
Authority
CA
Canada
Prior art keywords
vegfmg
polypeptide
expression
vegf
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002403804A
Other languages
English (en)
French (fr)
Inventor
Luca K. Rastelli
Hans-Peter Gerber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
CuraGen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2403804A1 publication Critical patent/CA2403804A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002403804A 2000-03-21 2001-03-21 Vegf-modulated genes and methods employing them Abandoned CA2403804A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19120100P 2000-03-21 2000-03-21
US60/191,201 2000-03-21
PCT/US2001/009043 WO2001070174A2 (en) 2000-03-21 2001-03-21 Vegf-modulated genes and methods employing them

Publications (1)

Publication Number Publication Date
CA2403804A1 true CA2403804A1 (en) 2001-09-27

Family

ID=22704517

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002403804A Abandoned CA2403804A1 (en) 2000-03-21 2001-03-21 Vegf-modulated genes and methods employing them

Country Status (6)

Country Link
US (3) US20020132978A1 (enExample)
EP (1) EP1290005A4 (enExample)
JP (1) JP2004501608A (enExample)
AU (2) AU2001250912B2 (enExample)
CA (1) CA2403804A1 (enExample)
WO (1) WO2001070174A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001278746A1 (en) * 2000-08-16 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Seamless soft capsule preparations containing dihydrobenzofuran derivatives
DE60238038D1 (de) * 2001-03-20 2010-12-02 Cns Protein Therapeutics Inc Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
EP1644406B1 (en) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2005082412A1 (ja) * 2004-02-26 2005-09-09 Perseus Proteomics Inc. 癌の治療および予防薬
WO2005094888A1 (ja) 2004-03-31 2005-10-13 Two Cells Co. Ltd. 損傷組織の治療剤と治療方法
MX2007010922A (es) * 2005-03-10 2007-10-12 Genentech Inc Metodos y composiciones para modular la integridad vascular.
PL1969003T3 (pl) 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
WO2009120810A2 (en) * 2008-03-25 2009-10-01 Cns Protein Therapeutics, Inc. Neurodegenerative disorders
JP5337868B2 (ja) 2008-04-23 2013-11-06 ノヴァセル テクノロジー インコーポレイテッド． 血管新生ペプチド
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
CA2730068A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
US20110229877A1 (en) 2008-07-07 2011-09-22 Oxford Nanopore Technologies Limited Enzyme-pore constructs
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
CN102215860A (zh) * 2008-08-05 2011-10-12 南佛罗里达大学 治疗认知损害的方法
EP2312896B1 (en) 2008-08-06 2018-01-10 Sharp Kabushiki Kaisha Base station device, mobile station device and corresponding communication methods using carrier aggregation
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
EP2391732B1 (en) 2009-01-30 2015-05-27 Oxford Nanopore Technologies Limited Methods using adaptors for nucleic acid constructs in transmembrane sequencing
CN102482330A (zh) * 2009-01-30 2012-05-30 牛津纳米孔技术有限公司 酶突变体
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
WO2012094600A1 (en) * 2011-01-06 2012-07-12 William Marsh Rice University Methods for treating lysosomal storage diseases using l-type ca2+ channel blockers with a 1,4 dihydropyridine structure and inhibitors of er-associated degradation
BR112013020411B1 (pt) 2011-02-11 2021-09-08 Oxford Nanopore Technologies Limited Monômero de msp mutante, construto, polinucleotídeo, poro, kit e aparelho para caracterizar uma sequência de ácido nucleico alvo, e, método para caracterizar uma sequência de ácido nucleico alvo
CA2838818A1 (en) * 2011-06-09 2012-12-13 University Of Miami Methods of treatment for retinal diseases
KR20140050067A (ko) 2011-07-25 2014-04-28 옥스포드 나노포어 테크놀로지즈 리미티드 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법
WO2013153359A1 (en) 2012-04-10 2013-10-17 Oxford Nanopore Technologies Limited Mutant lysenin pores
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
CA2901545C (en) 2013-03-08 2019-10-08 Oxford Nanopore Technologies Limited Use of spacer elements in a nucleic acid to control movement of a helicase
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
US10443097B2 (en) 2014-05-02 2019-10-15 Oxford Nanopore Technologies Ltd. Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
CN119899249A (zh) 2014-09-01 2025-04-29 弗拉芒区生物技术研究所 突变csgg孔
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
US11254738B2 (en) * 2016-09-07 2022-02-22 The Governing Council Of The University Of Toronto Banting Institute Synthetic antibodies against VEGF and their uses
EP3774858B1 (en) * 2018-03-29 2025-07-30 MyNeuroCure Oy C-terminal cdnf fragments having neuroprotective effect
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
EP3814492A4 (en) 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
KR20210068014A (ko) * 2018-08-20 2021-06-08 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT374041B (de) * 1982-03-25 1984-03-12 Naimer H L Stern-dreieck-schalter mit nullspannungsausloesung
US4758195A (en) * 1986-09-08 1988-07-19 3 W Designers, Inc. Elastomeric foam building units
FR2626254B1 (fr) * 1988-01-27 1990-07-06 Valois Sa Poussoir-etui avec systeme de garantie
US5174392A (en) * 1991-11-21 1992-12-29 Reinhardt Paul A Mechanically actuated fluid control device for downhole fluid motor
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4340891A1 (de) * 1993-12-01 1995-06-08 Mahle Gmbh Hubkolben für Verbrennungsmotoren aus insbesondere Leichtmetall
US5856103A (en) * 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US6410046B1 (en) * 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
WO2001019851A2 (en) * 1999-09-16 2001-03-22 Neurotrophic Bioscience Inc. Opaminergic neuronal survival-promoting factors and uses thereof
EP1225224A4 (en) * 1999-10-01 2004-03-24 Kyowa Hakko Kogyo Kk DNA THE SHEAR RESPONSE
MX2007010922A (es) * 2005-03-10 2007-10-12 Genentech Inc Metodos y composiciones para modular la integridad vascular.

Also Published As

Publication number Publication date
WO2001070174A2 (en) 2001-09-27
AU2001250912C1 (en) 2001-10-03
US20040006780A1 (en) 2004-01-08
US20080166724A1 (en) 2008-07-10
AU5091201A (en) 2001-10-03
WO2001070174A3 (en) 2002-04-11
EP1290005A2 (en) 2003-03-12
EP1290005A4 (en) 2005-04-20
JP2004501608A (ja) 2004-01-22
AU2001250912B2 (en) 2007-01-04
WO2001070174A8 (en) 2003-01-16
US20020132978A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
AU2001250912C1 (en) VEGF-modulated genes and methods employing them
AU2001250912A1 (en) VEGF-modulated genes and methods employing them
EP1265914B1 (en) Wnt-1 related polypeptides, and nucleic acids encoding the same
AU2001247781A1 (en) Novel polypeptides, and nucleic acids encoding the same
US20140030267A1 (en) Compositions, methods and kits relating to resistin
EP1265920B1 (en) Angiogenesis-associated proteins, and nucleic acids encoding the same
AU2001268715B2 (en) CGI-69 compositions and methods of use
AU2001249450A1 (en) Angiogenesis associated proteins, and nucleic acids encoding the same
US20030021788A1 (en) Novel human STRA6-like protein and nucleic acids encoding the same
US20060074023A1 (en) Angiogenesis associated proteins, and nucleic acids encoding the same
US20030104351A1 (en) FIZZ1 for metabolism regulation
AU2002254486A1 (en) FIZZ1 for metabolism regulation
AU2001297935A1 (en) Human Stra6-like protein and nucleic acids encoding the same
CA2447209A1 (en) Compositions and methods for adipose abundant protein
AU2002314808A1 (en) Compositions and methods for adipose abundant protein
WO2002097036A2 (en) Compositions and methods for adipose abundant protein

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued